Table 5 Current clinical trials of SMO inhibitors for leukemia patients
From: Advances in targeted therapy for acute myeloid leukemia
Agents | ClinicalTrials. gov Identifier | Phase | Enrollment Number | Disease Conditons | Status | Lead Institution/Location |
|---|---|---|---|---|---|---|
Glasdegib | NCT03416179 | 3 | 720 | AML | Recruiting | UCLA, USA |
NCT04051996 | 2 | 46 | AML | Recruiting | Yale Cancer Center, USA | |
NCT02367456 | 2 | 73 | AML, MDS | Active, not recruiting | University of Alabama at Birmingham, USA | |
NCT03390296 | 1/2 | 138 | R/R AML | Recruiting | M D Anderson Cancer Center, USA | |
NCT02038777 | 1 | 49 | AML | Recruiting | Japanese Red Cross Nagoya First Hospital,Japan | |
NCT01546038 | 2 | 255 | AML | Completed | University of Alabama at Birmingham, USA | |
Vismodegib | NCT02593760 | 1 | 19 | Myelofibrosis | Completed | Florida Cancer Specialists, USA |
Sonidegib | NCT01826214 | 2 | 70 | Acute Leukemia | Completed | Duke University Medical Center, USA |
NCT01456676 | 1 | 11 | CML | Completed | Novartis Investigative Site, Canada | |
NCT02129101 | 1 | 63 | CML de novo MDS | Completed | Mayo Clinic, USA |